Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat

European Journal of Pharmacology

Volumn 317, Issue 2-3, 1996, Pages 335-342

  Valentin, Jean Pierre ^a   Bessac, Anne Marie ^a   Maffre, Myriam ^a   John, Gareth W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

N( ) Nitro L arginine methyl ester (L NAME); Nitric oxide (NO); Pulmonary hypertension; SQ 29,548; TP receptor; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; THROMBOXANE B2; THROMBOXANE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANESTHESIA, GENERAL; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; HEMODYNAMIC PROCESSES; HYDRAZINES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; PULMONARY CIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOXANE; THROMBOXANE A2; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0030593942     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00735-2     Document Type: Article

References (34)

1. Barnes, P.J. and S.-F. Liu, 1995, Regulation of pulmonary vascular tone, Pharmacol. Rev. 47, 87.
2. 2 receptor activation elicits organ-specific increases in microvascular permeability in the rat, Am. J. Physiol. 268, R366.
3. 2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the vasculature of the rat in vivo, Br. J. Pharmacol. 115, 210.
4. 2 mimetic U-46619 induces systemic and pulmonary hypertension and delayed tachypnea in the goat, J. Appl. Physiol. 77, 1466.
5. ω-nitro-L-arginine methyl ester on arterial pressure and on vasodilator and vasoconstrictor responses: influence of initial vascular tone, Eur. J. Pharmacol. 212, 159.
6. Coleman, R.A., W.L. Smith and S. Narumiya, 1994, International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes, Pharmacol. Rev. 46, 205.
7. Cooper, C.J., M.J. Landzberg, T.J. Anderson, F. Charbonneau, M.A. Creager, P. Ganz and A.P. Selwyn, 1996, Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans, Circulation 93, 266.
8. Dinh-Xuan, A.T., T.W. Higenbottam, C.A. Clelland, J. Pepke-Zaba, G. Cremona, A.Y. Butt, S.R. Large, F.C. Wells and J. Wallwork, 1991, Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease, New Engl. J. Med. 324, 1539.
9. Fineman, J.R., R. Chang and S.J. Soifer, 1992, EDRF inhibition augments pulmonary hypertension in intact newborn lambs, Am. J. Physiol. 262, H1365.
10. 2 release, J. Pharmacol. Exp. Ther. 258, 669.
11. Frostell, C., M.-D. Fatacci, J.C. Wain, R. Jones and W.M. Zapol, 1991, Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction, Circulation 83, 2038.
12. Gardiner, S.M.A., A.M. Compton, T. Bennet, R.M.J. Palmer and S. Moncada, 1990, Control of regional blood flow by endothelium-derived nitric oxide, Hypertension 15, 486.
13. Giaid, A., and D. Saleh, 1995, Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension, New Engl. J. Med. 333, 214.
14. Hasunuma, K., T. Yamaguchi, D.M. Rodman, R.F. O'Brien and I.F. McMurty, 1991, Effects of inhibitors of EDRF and EDHF on vasoreactivity of perfused rat lungs, Am. J. Physiol. 260, L97.
15. Hyman, A.L., P.J. Kadowitz and H.L. Lippton, 1989, Methylene blue selectively inhibits pulmonary vasodilator responses in cats, J. Appl. Physiol. 66, 1513.
16. Ignarro, L.J., R.E. Byrns and K.S. Wood, 1987, Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein, Circ. Res. 60, 82.
17. Kaye, A.D., B.D. Nossaman, I.N. Ibrahim, B.J. DeWitt, C.-J. Feng and P.J. Kadowitz, 1995, Analysis of thromboxane receptor-mediated responses in the feline pulmonary vascular bed, Crit. Care Med. 23, 164.
18. G-nitro-L-arginine methyl ester on renal function and blood pressure, Am. J. Physiol. 267, L120.
19. McGregor, M. and A. Sniderman, 1985, On pulmonary vascular resistance: the need for more precise definition, Am. J. Cardiol. 55, 217.
20. ω-nitro-L-arginine methyl ester selectively inhibits pulmonary vasodilator responses to acetylcholine and bradykinin, J. Appl. Physiol. 71, 2026.
21. Moncada, S. and A. Higgs, 1993, The L-arginine-nitric oxide pathway, New Engl. J. Med. 329, 2002.
22. ω-Nitro-L-arginine and pulmonary vascular pressure-flow relationship in conscious dogs, Am. J. Physiol. 262, H1331.
23. Nossaman, B.D., T.J. McMahon, M.S. Ragheb, I.N. Ibrahim, C.R. Babycos, J.S. Hood and P.J. Kadowitz, 1992, Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban, Eur. J. Pharmacol. 213, 1.
24. Ogletree, M.L., D.N. Harris, R. Greenberg, M.F. Haslanger and M. Nakane, 1985, Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist, J. Pharmacol. Exp. Ther. 234, 435.
25. Peacock, A.J., 1995, Treatment of pulmonary hypertension, Drugs Today 31, 201.
26. Pepke-Zaba, J., T. Higenbottam, A. Dinh-Xuan, D. Stone and J. Wallwork, 1991, Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension, Lancet 338, 1173.
27. Perrella, M.A., F.L. Hildebrand Jr., K.B. Margulies and J.C. Burnett Jr., 1991, Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function, Am. J. Physiol. 261, R323.
28. Rees, D.D., R.M.J. Palmer and S. Moncada, 1989, Role of endothelium-derived nitric oxide in the regulation of blood pressure, Proc. Natl. Acad. Sci. USA 86, 3375.
29. Rubin, L.J., 1995, Pathology and pathophysiology of primary pulmonary hypertension, Am. J. Cardiol. 75, 51A.
30. Stamler, J.S., E. Loh, M.-A. Roddy, K.E. Currie and M.A. Creager, 1994, Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans, Circulation 89, 2035.
31. Wang, Y.-X., I. Gavras, T. Wierzba, B. Lammek and H. Gavras, 1992, Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension 19 (Suppl. 2), 255.
32. G-nitro-L-arginine methyl ester (L-NAME) of resistance to venous return in rats, Br. J. Pharmacol. 114, 1454.
33. Wiklund, N.P., M.G. Persson, L.E. Gustafsson, S. Moncada and P. Hedqvist, 1990, Modulatory role of endogenous nitric oxide in pulmonary circulation in vivo, Eur. J. Pharmacol. 185, 123.
34. Xue, C., A. Rengasamy, T.D. Le Gras, P.A. Koberna, G.C. Dailey and R.A. Johns, 1994, Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia, Am. J. Physiol. 267, L667.